News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

MAKO Surgical Corp. Showcases MAKOplasty(R) Total Hip Arthroplasty at American Academy of Orthopaedic Surgeons 2012 Annual Meeting

2/8/2012 10:40:17 AM

SAN FRANCISCO, Feb. 8, 2012 /PRNewswire/ -- MAKO Surgical Corp. (NASDAQ: MAKO), a leader in robotic arm assisted partial knee arthroplasty worldwide, today announced the MAKOplasty® Total Hip Arthroplasty (THA) application will be featured at the American Academy of Orthopaedic Surgeons 2012 Annual Meeting (AAOS) being held on February 7-11, 2012 at the Moscone Center in San Francisco, California.

MAKOplasty® THA is the newest application for MAKO's RIO® Robotic Arm Interactive Orthopedic System. The RIO® system will be on exhibit at MAKO's AAOS Annual Meeting Booth #2353. During the meeting, experienced MAKOplasty® orthopedic surgeons will give presentations and hands-on demonstrations of the MAKOplasty® THA application.

"There is clearly a need for precision and accuracy in total hip replacement. We believe the RIO® system, which enables surgeons to achieve consistently reproducible precision for the individual patient, along with our MAKOplasty® THA, are key drivers in leading our growing presence in orthopedic surgery," said Maurice R. Ferr, M.D., president and CEO of MAKO.

MAKOplasty® THA builds upon MAKOplasty® Partial Knee Resurfacing's proven benefits for patients with early to mid-stage osteoarthritis of the knee. To date, nearly 13,000 patients have benefited from MAKOplasty® partial knee and total hip procedures. In 2012, MAKO anticipates to perform 11,000 to 13,000 MAKOplasty® procedures.

MAKOplasty® THA was introduced in 2011 and is designed to support a surgeon's ability to more accurately align and position a hip implant relative to the specific needs of a patient. It provides a surgeon with a pre-operative 3-D reconstruction of a patient's hip that is used to develop a patient-specific surgical plan. The surgeon then uses the RIO® robotic arm during the procedure to prepare the joint and optimally place the hip implant to the plan.

As of December 31, 2011, 49 MAKOplasty® THA applications have been sold in the U.S.; hospitals in California, New York, and Florida are among many locations nationwide now offering MAKOplasty® THA.

More information about MAKOplasty® can be found at

About MAKO Surgical Corp.
MAKO Surgical Corp. is a medical device company that markets its RIO® Robotic-Arm Interactive Orthopedic system, joint specific applications for the knee and hip, and proprietary RESTORIS® implants for orthopedic procedures called MAKOplasty®. The RIO is a surgeon-interactive tactile surgical platform that incorporates a robotic arm and patient-specific visualization technology, which enables precise, consistently reproducible bone resection for the accurate insertion and alignment of MAKO's RESTORIS implants. The MAKOplasty solution incorporates technologies enabled by an intellectual property portfolio including more than 300 U.S. and foreign, owned and licensed, patents and patent applications. Additional information can be found at

Forward-Looking Statements

This press release contains forward-looking statements regarding, among other things, statements related to expectations, goals, plans, objectives and future events. MAKO intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Reform Act of 1995. In some cases, forward-looking statements can be identified by the following words: "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing," "guidance" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Examples of such statements include, but are not limited to, statements about the nature, timing and number of planned new product introductions; market acceptance of MAKOplasty, including the RIO system, and MAKO RESTORIS® family of implant systems; the future availability from third-party suppliers, including single source suppliers, of implants for and components of the RIO system; the anticipated adequacy of our capital resources to meet the needs of MAKO's business; MAKO's ability to sustain, and MAKO's goals for, sales and earnings growth including projections regarding systems installations; and MAKO's success in achieving timely approval or clearance of products with domestic and foreign regulatory entities. These statements are based on the current estimates and assumptions of our management as of the date of this press release and are subject to risks, uncertainties, changes in circumstances, assumptions and other factors that may cause actual results to differ materially from those indicated by forward-looking statements, many of which are beyond MAKO's ability to control or predict. Such factors, among others, may have a material adverse effect on MAKO's business, financial condition and results of operations and may include the potentially significant impact of a continued economic downturn or delayed economic recovery on the ability of MAKO's customers to secure adequate funding, including access to credit, for the purchase of MAKO's products or cause MAKO's customers to delay a purchasing decision, changes in competitive conditions and prices in MAKO's markets, unanticipated issues relating to intended product launches, decreases in sales of MAKO's principal product lines, decreases in utilization of MAKO's principal product line or in procedure volume, increases in expenditures related to increased or changing governmental regulation or taxation of MAKO's business, both nationally and internationally, unanticipated issues in complying with domestic or foreign regulatory requirements related to MAKO's current products or securing regulatory clearance or approvals for new products or upgrades or changes to MAKO's current products, the impact of the recently enacted United States healthcare reform legislation on hospital spending, reimbursement, and the taxing of medical device companies, the potential impact of the informal Securities and Exchange Commission inquiry and the findings of that inquiry, loss of key management and other personnel or inability to attract such management and other personnel and unanticipated intellectual property expenditures required to develop, market, and defend MAKO's products. These and other risks are described in greater detail under Item 1A, "Risk Factors," in MAKO's periodic filings with the Securities and Exchange Commission, including MAKO's annual report on Form 10-K for the year ended December 31, 2010 filed on March 10, 2011 and quarterly report on Form 10-Q for the quarter ended September 30, 2011 filed on November 9, 2011. Given these uncertainties, undue reliance should not be placed on these forward-looking statements. MAKO does not undertake any obligation to release any revisions to these forward-looking statements publicly to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

"MAKOplasty®," "RESTORIS®," "RIO®," as well as the "MAKO" logo, whether standing alone or in connection with the words "MAKO Surgical Corp." are trademarks of MAKO Surgical Corp.

SOURCE MAKO Surgical Corp.

Read at

comments powered by Disqus